The DOI matches its Crossref record.
Photoactivatable Platinum Complexes
Abstract
The development of photoactivatable prodrugs of platinum-based antitumor agents is aimed at increasing the selectivity and hence lowering toxicity of this important class of antitumor drugs. These drugs could find use in treating localized tumors accessible to laser-based fiber-optic devices. PtIV complexes appeared attractive because these octahedral complexes are usually substitution inert and require reduction to the PtII species to become cytotoxic. Based on the knowledge of PtIV photochemistry, Pt IV analogs of cisplatin, [Pt(en)Cl2] and transplatin were designed, synthesized and investigated for their ability to be photoreduced to cytotoxic PtII species. Two classes of photoactivatable Pt complexes have been looked at thus far: diiodo-PtIV and diazido-Pt IV diam(m)ine complexes. The first generation, diiodo-PtIV complexes, represented by cis, trans-[Pt(en)(I)2(OAc)2], react to visible light by binding irreversibly to DNA and forming adducts with 5-GMP in the same manner as [Pt(en)Cl2]. Furthermore, the photolysis products are cytotoxic to human cancer cells in vitro. However, these complexes are too reactive towards biological thiols (i.e., glutathione), which rapidly reduced them to cytotoxic PtII species, thus making them unsuitable as drugs. The second generation, diazido-PtIV complexes, represented by cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] and cis, trans-[Pt(en)(N3)2(OH)2], are also photosensitive, binding irreversibly to DNA and forming similar products with DNA and 5-GMP in the presence of light as the respective PtII complexes. However, they are stable to glutathione and thus show very low dark cytotoxicity. Light of lirr = 366 nm activates both complexes to cytotoxic species that effectively kill cancer cells by destroying their nuclei, leaving behind shrunken cell ghosts. Interestingly, the all-trans analog, trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] is non-toxic to HaCaT keratinocytes in the dark, but as active as cisplatin in the light. These studies show that photoactivatable PtIV antitumor agents represent a promising area for new drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Self-citationToward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Using coordination chemistry to design new medicines
Ronconi, L., & Sadler, P. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2006.11.017 · Cited by 608
Self-citationInorganic Nanoparticles in Cancer Therapy
Bhattacharyya, S., Kudgus, R. A., Bhattacharya, R., & Mukherjee, P. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0318-0 · Cited by 395
Photoactivated Biological Activity of Transition‐Metal Complexes
Schatzschneider, U. (2010) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201000003 · Cited by 349
Metadata
- Authors
- Bednarski, P. J., Mackay, F. S., & Sadler, P. J.
- Venue
- Anti-Cancer Agents in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 75-93
- ISSN
- 1568-0118 (ISSN-L)
- 1871-5206
- OpenAlex
- W2108950213
- Cited by
- 244
- References
- 0
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Photoactivatable Platinum Complexes. https://app.cochat.ai/papers/10.2174/187152007779314053
- The paper
- Bednarski, P. J., Mackay, F. S., & Sadler, P. J. (2007). Photoactivatable Platinum Complexes. Anti-Cancer Agents in Medicinal Chemistry. https://doi.org/10.2174/187152007779314053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.